Last reviewed · How we verify
Tarlige (MIROGABALIN)
Mirogabalin, also known as Tarlige, is a small molecule modality developed by Daiichi Sankyo Company, Limited. It targets the voltage-dependent calcium channel subunit alpha-2/delta-1, which plays a crucial role in pain transmission. Mirogabalin is approved for the treatment of diabetic peripheral neuropathy, peripheral neuropathic pain, and postherpetic neuralgia. The commercial status of Mirogabalin is not explicitly stated, but it is still owned by Daiichi Sankyo Company, Limited. Key safety considerations include its mechanism of action, which may have implications for patients with certain medical conditions.
At a glance
| Generic name | MIROGABALIN |
|---|---|
| Sponsor | Daiichi Sankyo |
| Target | Voltage-dependent calcium channel subunit alpha-2/delta-1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| Annual revenue | 300 |
Approved indications
- Diabetic peripheral neuropathy
- Peripheral neuropathic pain
- Postherpetic neuralgia
Common side effects
Key clinical trials
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain (PHASE4)
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia (NA)
- Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA (NA)
- Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults (PHASE1)
- A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
- Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors (NA)
- Study of Mirogabalin for Central Neuropathic Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tarlige CI brief — competitive landscape report
- Tarlige updates RSS · CI watch RSS
- Daiichi Sankyo portfolio CI